March 8th 2024
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
February 27th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Encouraging Responses Seen With Selinexor in Relapsed/Refractory DLBCL
December 19th 2018According to findings from the phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.
Read More
Subgroup Analysis Highlights Brentuximab Vedotin Benefit in Nonpediatric AYA Hodgkin Lymphoma
December 17th 2018In findings reported during the 2018 ASH Annual Meeting, brentuximab vedotin with conventional chemotherapy significantly improved progression-free survival compared with standard therapy for nonpediatric patients with stage III/IV Hodgkin lymphoma.
Read More
Brentuximab Vedotin Demonstrates Survival Benefit Over CHOP in CD30+ PTCL
December 6th 2018According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in <em>Lancet Oncology</em>.
Read More
Significant PFS Benefit Seen With R2 Regimen in Indolent NHL
December 4th 2018Lenalidomide in addition to rituximab, called the R<sup>2</sup> regimen, led to a significant increase in progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma in results from the phase III AUGMENT trial.
Read More
Responses Seen in Relapsed/Refractory FL and DLBCL With Mosunetuzumab
December 3rd 2018Mosunetuzumab, a CD3 and CD20 bispecific antibody, induced complete remission rates over 30% in patients with relapsed/refractory follicular lymphoma and relapsed/refractory diffuse large B-cell lymphoma or transformed follicular lymphoma, and demonstrated a tolerable safety profile, showing promise for these patients with B-cell indolent and aggressive non-Hodgkin lymphomas.
Read More
First-Line R-CHOP a Viable Option in Advanced Follicular Lymphoma, Long-Term Findings Show
December 1st 2018Two variants of the chemotherapy regimen R-CHOP resulted in comparable overall survival and progression-free survival in patients with previously untreated stage III or IV indolent B-cell lymphoma, including grades 1 to 3 follicular lymphoma, according to a long-term follow-up analysis from a combined phase II/III randomized trial.
Read More
Lenalidomide Combo Shows Promise as Frontline Treatment in Follicular Lymphoma
November 30th 2018The immunomodulating agent lenalidomide induced a complete response in 74% of patients with high tumor burden follicular lymphoma when used in combination with rituximab and a 4-drug chemotherapy regimen, according to a recent study.
Read More
FDA Approves Rituximab Biosimilar for Treatment of Non-Hodgkin Lymphoma
November 29th 2018The FDA has granted approval to the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy, making it the first biosimilar approved by the FDA for the treatment of patients with NHL.
Read More
Findings From the RELEVANCE Trial in Follicular Lymphoma
November 28th 2018Andre Goy, MD, chairman and director, chief of lymphoma, and director of clinical and translational cancer research at John Theurer Cancer Center, discusses data from the RELEVANCE trial, which randomized patients with follicular lymphoma in need of therapy to receive either rituximab plus lenalidomide or a physician’s choice of bendamustine and rituximab plus CHOP or R-CHOP.
Watch
What Is the Role of SCT as Novel Agents Emerge for Relapsed/Refractory HL?
November 19th 2018During a presentation at the National Comprehensive Cancer Network 13th Annual Conference: Hematologic Malignancies Phillippe Armand, MD, PhD, discusses how novel agents could be used in the future either to postpone, permit, or even replace allogeneic stem cell transplantation.
Read More
Small Molecule Inhibitors Prove Effective in Targeting NHL
November 17th 2018A greater understanding of molecular pathogenesis in non-Hodgkin lymphoma has led to the identification of rational targets for novel small molecule inhibitors, according to Andrew D. Zelenetz, MD, PhD. Combinations of these therapies may also provide greater responses and the potential for therapy discontinuation.
Read More
Brentuximab Vedotin Granted FDA Approval for Frontline CD30+ PTCL
November 16th 2018Brentuximab vedotin (Adcetris) has been granted FDA approval for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma, based on findings from the phase III ECHELON-2 trial.
Read More
Brentuximab Vedotin Submitted for FDA Approval in Frontline CD30+ PTCL
November 6th 2018Based on findings from the phase III ECHELON-2 trial, brentuximab vedotin (Adcetris) has been submitted to the FDA for approval in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
Read More
Experts Remark on CAR T-Cell Therapy at 1-Year Milestone, Where It Is Headed
October 19th 2018With 2 CAR T-cell therapies now approved and more moving quickly through early-phase clinical trials, 4 healthcare experts reflected on the evolving field of CAR T-cell therapy, their understanding of its current and future applicability for patients, the process for administration and the challenges and obstacles that remain unaddressed during an Association of Community Cancer Centers interactive panel.<br />
Read More
ODAC Recommends FDA Approval of Rituximab Biosimilar
October 10th 2018In a 16-0 vote, the FDA’s Oncologic Drugs Advisory Committee has recommended the approval of the rituximab biosimilar CT-P10 for 3 of the anti-CD20 monoclonal antibody’s non-Hodgkin lymphoma indications.
Read More
ILROG Guidelines Recommend Proton Therapy to Limit Damage to OARs in Mediastinal Lymphomas
October 10th 2018Guidelines from the International Lymphoma Radiation Oncology Group recommend the use of proton therapy in adults with mediastinal lymphomas and for young women. Specifically, clinicians should consider proton therapy in mediastinal disease that spans below the left main stem coronary artery and is near the front of, behind, or on the left side of the heart.
Read More
Survival Improvement Seen With Frontline Brentuximab Vedotin in CD30+ PTCL
October 2nd 2018Patients with CD30-expressing peripheral T-cell lymphoma who were treated with the combination of brentuximab vedotin and frontline chemotherapy experienced a statistically significant improvement in progression-free and overall survival, according to topline results from the phase III ECHELON-2 trial.
Read More
Pontchartrain Cancer Center Pushes Limits of Community Care in Southeast Louisiana
September 27th 2018Pontchartrain Cancer Center was founded in 2005 to serve an area of Louisiana that lacked the necessary resources for cancer care. This community cancer center, with 2 locations in Southeast Louisiana, accommodates any patient to walk through its doors, filling a major unmet need for the community in this rural area.
Read More
Duvelisib Granted FDA Approval for CLL and Follicular Lymphoma
September 25th 2018Duvelisib (Copiktra) has been approved by the FDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma. Both indications are for the treatment of patients who have received at least 2 prior therapies.
Read More
Axicabtagene Ciloleucel Gains Approval in Europe for DLBCL, PMBCL
August 28th 2018Axicabtagene ciloleucel (axi-cel; Yescarta) has been approved by the European Commission as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, following at least 2 lines of systemic therapy.
Read More
Tisagenlecleucel Granted Approval in Europe for DLBCL, ALL
August 27th 2018Tisagenlecleucel has gained approval from the European Commission as a treatment for adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
Read More
Targeting EZH2 Delivers Promising Activity in Lymphomas
August 17th 2018Targeting EZH2, the catalytic subunit of the multiprotein PRC2, may represent an attractive therapeutic objective in malignant lymphoma, Vincent Ribrag, MD, told his audience at the American Association for Cancer Research’s inaugural Advances in Malignant Lymphoma meeting.
Read More